Sentences with phrase «car was no t»

One of the most notable additions to the 2017 cars is the T - wing, which has been trialled a Mercedes and a few other teams in testing so far.

My car is a T reg Volvo S40 2.0 l with 130,000 miles.

Live an hour away and half hour before appt another more senior rep called and said car was no t available.

@ weeks after purchasing the car we were T - boned by a driver go full speed thru a stop sign without attempting to stop.

Broadside crashes happen when one car is T - boned by another car.

Not exact matches

That also means Novartis will be taking on rival Gilead, which is the only other company to have an approved CAR - T therapy on the market (both received the regulatory green light in 2017).

What makes the treatment so fascinating is its underlying technology, called chimeric antigen receptor T - cell (CAR - T).

There are still plenty of challenges ahead for Novartis and other companies in the CAR - T space.

They're known as CAR - T therapies.

The treatment is a type of so - called CAR T - cell therapy — taking a patient's own immune cells, called T cells, genetically manipulating them to attack specific proteins on cancer, and infusing them back into the patient.

TapouT was launched as a T - shirt peddling business out of the trunk of a car in 1997.

Grasso is long stock AAPL, BABA, CAR, EVGN, JCP, MJNA, MON, OSTK, PHM, SQ, T, TWTR, VRX.

Steve Grasso is long stock AAPL, BABA, CAR, EVGN, FB, JCP, MJNA, MON, OSTK, PFE, RAD, SQ, T, TWTR, VRX.

Those two companies, along with their larger competitor Novartis (nvs), are developing experimental chimeric antigen receptor T - cell (CAR - T) technology platforms, which are highly personalized treatments that involve extracting patients» immune cells, re-engineering them to target their specific cancers, and then pumping these sniper - cells back into the body.

As regular readers know, CAR - T is one of the most closely watched experimental cancer technologies in the world right now.

With the Kite deal, Gilead is significantly expanding its footprint in a multi-billion dollar treatment space and will be one of the first entrants into the new CAR - T market if KTE - C19 wins approval in the fall.

The deal will give Gilead access to KTE - C19, which is a chimeric antigen receptor T - cell (CAR - T) therapy.

Gilead, fresh from its CAR - T cancer drug victory last year, has struck a deal with gene - editing specialist Sangamo that could be worth up to $ 3 billion (with $ 150 million in upfront cash).

Importantly, the deal also means that Gilead / Kite rival Novartis (which had its own CAR - T drug approved ahead of Yescarta) and other CAR - T companies won't be able to get in on Sangamo's platform.

Merck and Bristol - Myers Squibb each have approved immunotherapy drugs, while Gilead Sciences announced Monday it plans to acquire Kite Pharma for $ 11.9 billion, just a few months before the FDA is expected to approve Kite's CAR - T drug for lymphoma on Nov. 29.

CAR - T cell therapy is a form of immunotherapy, a rapidly developing cancer treatment that uses patients» own immune cells to attack tumors.

After it was reported that Rob Ford supporters had asked him to sign «Ford Nation» t - shirts adorned with the blue Ford Motor company logo at a charity event, the car manufacturer moved to protect its trademark from unauthorized use.

One of the top contributors to the gain was bluebird bio, which is also working on CAR - T cell therapy.

Bellicum is among the flurry of biotechs investing heavily into cell therapies such as experimental chimeric antigen receptor T - cell (CAR - T) treatments for cancer (this is the next - gen treatment that involves reprogramming immune cells to become cancer killers and has shown promise in blood cancers, which Bellicum specializes in).

Kymriah is the first CAR - T cell therapy to get approved, and several more are in the works.

CAR - T's side effects can be deadly.

Satwani — who hasn't delivered the CAR - T therapy but is heading up the program at Columbia, one of the 32 sites Novartis will use — said patients would need to be monitored closely for about a month, meaning they'd need to be less than a two - hour drive from their hospital.

SAAB Automobile Australia is celebrating reduced GST car prices with Limited Edition extras for the Saab 9 - 3 TS Coupe and S Sedan to create the best value entry car in Australia at $ 49,990.

Yescarta is a so - called chimeric antigen receptor T - cell (CAR - T) treatment.

Kite Pharma, Juno Therapeutics, and Bluebird Bio are among a growing group of biotech companies working with CAR - T.

JCAR015 is among CAR T - cell candidates covered by Juno's 10 - year, approximately $ 1 billion global collaboration launched in 2015 to develop and commercialize cancer and autoimmune diseases immunotherapies.

The company's CAR T - cell cancer immunotherapy furthest in development at present is JCAR017.

However, those statements needed to be clarified when the investigation was completed, as no such link was proven: «[t] here is absolutely no evidence so far that terrorists used any bitcoin in financing their actions or why would they not simply use cash if the purpose is just to rent a getaway car, mobile phones or anything else they don't want tracked.»

' T is the season for buying a new car.

Kite is one of the leading players in the emerging field of CAR T, and is competing with rivals Novartis AG, Juno Therapeutics Inc and Bluebird Bio Inc in a race to get the first approved therapy.

Santa Monica, California - based Kite is developing chimeric antigen receptor T - cell therapy, known as a CAR T, which harnesses the body's own immune cells to recognize and attack malignant cells.

The U.S. Food and Drug Administration (FDA) is expected to decide by Nov. 29 whether to approve Kite's CAR T, axi - cel, for treatment of adults with advanced lymphoma.

These CAR - T cells were able to penetrate the blood - brain barrier, one of the major hurdles in treating brain tumors.

«Many investors expected a more lengthy FDA review process of the JCAR015 trial (and potentially other CAR - T programs) and feared that a higher - degree regulatory scrutiny could increase the development risk of CAR T cell,» Leerink Research said in a note co-authored by analysts Michael Schmidt, Ph.D., Jonathan Chang, Ph.D., and Varun Kumar, Ph.D. «While it may take several weeks to reopen all clinical sites of the ROCKET trial, we believe the trial shouldn't be delayed by more than ~ 3 months.»

Kymriah — the first CAR - T ever to get approval — is now also the first CAR - T to get approval for two distinct indications in non-Hodgkin lymphoma (NHL) and B - cell ALL.

JCAR015 is a CD19 - directed chimeric antigen receptor technology (CAR - T) product candidate that has been under study in ROCKET in adult patients with relapsed or refractory B - cell acute lymphoblastic leukemia.

Gilead $ GILD has agreed to buy CAR - T pioneer Kite Pharma $ KITE — which is likely just months away from its first approval — for $ 11.9 billion in cash.

At this time, trials and plans for its other CD19 - directed chimeric antigen receptor (CAR) T - cell product candidates, including JCAR017, are not affected.

After disappointing investors this year with sluggish sales, the prospects for Novartis» CAR - T therapy Kymriah may be improving.

Dr. Newman added that rival CAR T cell therapy developer Kite Pharma was still likelier to generate more revenue than Juno with KTE - C19, which last week completed patient enrollment in the Phase II portion of the ZUMA - 1 trial in patients with diffuse large B - cell lymphoma.

«The Model T set Ford's reputation as a car company early on, but I'm here to tell you we made a heck of a lot of Model T Ford trucks way back then, as well,» Kreipke said.

At EMD Serono, he was Senior Vice President and Global Senior Scientific Advisor in Immunology and Immuno - Oncology, facilitating major academic center alliances and running the CAR T - cell program in partnership with Intrexon.

But what if CAR - T therapy is obsolete before it even gets started?

It is also a potential economic windfall for the companies developing CAR - T therapies.

Going back to the Model T Ford, the car was essentially a wagon with a gasoline engine.